LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 65

Search options

  1. Article ; Online: Greenness assessment of microextraction techniques in therapeutic drug monitoring.

    Pour, Parastoo Hosseini / Suzaei, Foad Mashayekhi / Daryanavard, Seyed Mosayeb

    Bioanalysis

    2024  

    Abstract: Aim: ...

    Abstract Aim:
    Language English
    Publishing date 2024-03-11
    Publishing country England
    Document type Journal Article
    ISSN 1757-6199
    ISSN (online) 1757-6199
    DOI 10.4155/bio-2023-0266
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: In Situ

    Sorouri, Farzaneh / Hosseini, Parastoo / Sharifzadeh, Mohammad / Kiani, Sahar / Khoobi, Mehdi

    ACS applied materials & interfaces

    2023  Volume 15, Issue 36, Page(s) 42251–42270

    Abstract: Dysfunctional clinical outcomes following spinal cord injury (SCI) result from glial scar formation, leading to the inhibition of new axon growth and impaired regeneration. Nevertheless, nerve regeneration after SCI is possible, provided that the state ... ...

    Abstract Dysfunctional clinical outcomes following spinal cord injury (SCI) result from glial scar formation, leading to the inhibition of new axon growth and impaired regeneration. Nevertheless, nerve regeneration after SCI is possible, provided that the state of neuron development in the injured environment is improved. Hence, biomaterial-based therapy would be a promising strategy to endow a desirable environment for tissue repair. Herein, we designed a novel multifunctional injectable hydrogel with antioxidant, neuroprotective, and neuroregenerative effects. Bucladesine-encapsulated chitosan nanoparticles (BCS NPs) were first prepared and embedded in a matrix of thiol-functionalized hyaluronic acid modified with ferulic acid (HASH-FA). The target hydrogel (HSP-F/BCS) was then created through Michael-type addition between HASH-FA containing BCS NPs and four-arm polyethylene glycol-maleimide (4-Arm-PEG-Mal). The obtained hydrogel with shear thinning behavior showed viscoelastic and mechanical properties similar to the normal nerve tissue. FA conjugation significantly improved the antioxidant activity of HA, and suppressed intracellular ROS formation.
    MeSH term(s) Animals ; Rats ; Bucladesine ; Axons ; Gliosis ; Spinal Cord Injuries/drug therapy ; Spinal Cord Regeneration ; Antioxidants/pharmacology ; Hydrogels/pharmacology
    Chemical Substances ferulic acid (AVM951ZWST) ; Bucladesine (63X7MBT2LQ) ; Antioxidants ; Hydrogels
    Language English
    Publishing date 2023-08-30
    Publishing country United States
    Document type Journal Article
    ISSN 1944-8252
    ISSN (online) 1944-8252
    DOI 10.1021/acsami.3c08366
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Role of hemagglutinin esterase in replication of SARS-CoV-2.

    Zandi, Milad / Soltani, Saber / Hosseini, Parastoo

    Expert opinion on therapeutic targets

    2021  Volume 25, Issue 10, Page(s) 909

    MeSH term(s) COVID-19 ; Hemagglutinins, Viral ; Humans ; SARS-CoV-2 ; Viral Fusion Proteins
    Chemical Substances Hemagglutinins, Viral ; Viral Fusion Proteins ; hemagglutinin esterase
    Language English
    Publishing date 2021-11-18
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2055208-7
    ISSN 1744-7631 ; 1472-8222
    ISSN (online) 1744-7631
    ISSN 1472-8222
    DOI 10.1080/14728222.2021.1999417
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Molecular characterization of the neuraminidase gene of

    Kaveh, Kimia / Tazarghi, Abbas / Hosseini, Parastoo / Fotouhi, Fatemeh / Ajorloo, Mehdi / Rabiei Roodsari, Mehdi / Razavi Nikoo, Hadi

    Virusdisease

    2023  Volume 34, Issue 1, Page(s) 21–28

    Abstract: Neuraminidase inhibitors are the only FDA-approved class of antiviral agents ... ...

    Abstract Neuraminidase inhibitors are the only FDA-approved class of antiviral agents against
    Language English
    Publishing date 2023-02-14
    Publishing country India
    Document type Journal Article
    ZDB-ID 2846993-8
    ISSN 2347-3517 ; 2347-3584
    ISSN (online) 2347-3517
    ISSN 2347-3584
    DOI 10.1007/s13337-022-00806-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Investigating the effect of

    Hosseini, Parastoo / Rahimi Foroushani, Abbas / Marjani, Arezoo / Tavakoli, Mahnaz / Amiri, Abdollah / Hosseini, Amin / Bahavar, Atefeh / Mozhgani, Sayed-Hamidreza / Norouzi, Mehdi

    Iranian journal of microbiology

    2023  Volume 15, Issue 3, Page(s) 475–481

    Abstract: Background and objectives: HTLV-1 is responsible for two important diseases, HAM/TSP and ATLL. Approximately 10 to 20 million people are infected with HTLV-1 worldwide. Identifying altered genes in different cancers is crucial for finding potential ... ...

    Abstract Background and objectives: HTLV-1 is responsible for two important diseases, HAM/TSP and ATLL. Approximately 10 to 20 million people are infected with HTLV-1 worldwide. Identifying altered genes in different cancers is crucial for finding potential treatment strategies. One of the proteins of the RAS/MAPK signaling pathway is MEK1, which is made from the
    Materials and methods: Ten ATLL and 10 healthy control individuals were investigated in this study. We used ELISA test to screen anti-HTLV-I antibodies and PCR for confirmation of infection. Then, we extracted total RNA from fresh whole blood, and cDNA was synthesized. The expression levels of the
    Results: MAP2K1
    Conclusion: These results could be a perspective in the prevention, prognosis, and targeted treatment of diseases in which the
    Language English
    Publishing date 2023-06-28
    Publishing country Iran
    Document type Journal Article
    ZDB-ID 2652849-6
    ISSN 2008-4447 ; 2008-3289
    ISSN (online) 2008-4447
    ISSN 2008-3289
    DOI 10.18502/ijm.v15i3.12910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Anti-inflammatory Effects of Ziziphus Jujube Mill on LPS-induced Acute Lung Injury in Mice.

    Shaban, Parastoo / Honari, Niloofar / Erfanian, Nafiseh / Hosseini, Mehran / Safarpour, Hossein / Nasseri, Saeed

    Iranian journal of allergy, asthma, and immunology

    2023  Volume 22, Issue 3, Page(s) 281–289

    Abstract: Ziziphus Jujuba Mill (Z.J) is a well-known ethnomedical source of biologically active compounds with anti-inflammatory effects. However, its significance in acute lung injury (ALI) has never been studied. The present study aimed to explore whether Z.J ... ...

    Abstract Ziziphus Jujuba Mill (Z.J) is a well-known ethnomedical source of biologically active compounds with anti-inflammatory effects. However, its significance in acute lung injury (ALI) has never been studied. The present study aimed to explore whether Z.J could attenuate lipopolysaccharide (LPS)-induced inflammatory responses in an experimental model of ALI. Male BALB/c mice received an intratracheal administration of LPS (n=32) or phosphate buffer saline (PBS) (control, n=8). Within 1, 11, and 23 h post-LPS injection, mice were randomly assigned to receive intraperitoneal treatments of saline, dexamethasone (2 mg/kg), and 100 and 200 mg/kg of Z.J extracts, respectively. 24 h after intratracheal administration of LPS, bronchoalveolar lavage fluid and lung tissues were harvested and assessed for inflammatory cell influx, tumor necrosis factor-α (TNF-α) levels, and histological assessments. Treatment with Z.J extracts (100 and 200 mg/kg) and dexamethasone effectively reduced LPS-induced neutrophil and other inflammatory cell influx into the lung tissue compared to the untreated group. additionally, both doses of Z.J extracts (100 and 200 mg/kg) significantly ameliorated the lung wet-to-dry ratio and histopathological damage. Furthermore, compared to the untreated ALI mice, Z.J extract at the highest dose could significantly reduce the TNF-α level.   The present findings indicated that Z.J could effectively ameliorate LPS-induced ALI inflammatory responses and might be considered a promising alternative therapy for the ALI phenotype.
    MeSH term(s) Mice ; Male ; Animals ; Lipopolysaccharides/pharmacology ; Ziziphus ; Tumor Necrosis Factor-alpha ; Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Acute Lung Injury/pathology ; Lung/pathology ; Bronchoalveolar Lavage Fluid ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Dexamethasone/adverse effects ; Mice, Inbred BALB C ; NF-kappa B
    Chemical Substances Lipopolysaccharides ; Tumor Necrosis Factor-alpha ; Anti-Inflammatory Agents ; Dexamethasone (7S5I7G3JQL) ; NF-kappa B
    Language English
    Publishing date 2023-06-16
    Publishing country Iran
    Document type Journal Article
    ZDB-ID 2488724-9
    ISSN 1735-5249 ; 1735-1502
    ISSN (online) 1735-5249
    ISSN 1735-1502
    DOI 10.18502/ijaai.v22i3.13056
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Anti-inflammatory Effects of Ziziphus Jujube Mill on LPS-induced Acute Lung Injury in Mice

    Parastoo Shaban / Niloofar Honari / Nafiseh Erfanian / Mehran Hosseini / Hossein Safarpour / Saeed Nasseri

    Iranian Journal of Allergy, Asthma and Immunology, Vol 22, Iss

    2023  Volume 3

    Abstract: Ziziphus Jujuba Mill (Z.J) is a well-known ethnomedical source of biologically active compounds with anti-inflammatory effects. However, its significance in acute lung injury (ALI) has never been studied. The present study aimed to explore whether Z.J ... ...

    Abstract Ziziphus Jujuba Mill (Z.J) is a well-known ethnomedical source of biologically active compounds with anti-inflammatory effects. However, its significance in acute lung injury (ALI) has never been studied. The present study aimed to explore whether Z.J could attenuate lipopolysaccharide (LPS)-induced inflammatory responses in an experimental model of ALI. Male BALB/c mice received an intratracheal administration of LPS (n=32) or phosphate buffer saline (PBS) (control, n=8). Within 1, 11, and 23 h post-LPS injection, mice were randomly assigned to receive intraperitoneal treatments of saline, dexamethasone (2 mg/kg), and 100 and 200 mg/kg of Z.J extracts, respectively. 24 h after intratracheal administration of LPS, bronchoalveolar lavage fluid and lung tissues were harvested and assessed for inflammatory cell influx, tumor necrosis factor-α (TNF-α) levels, and histological assessments. Treatment with Z.J extracts (100 and 200 mg/kg) and dexamethasone effectively reduced LPS-induced neutrophil and other inflammatory cell influx into the lung tissue compared to the untreated group. additionally, both doses of Z.J extracts (100 and 200 mg/kg) significantly ameliorated the lung wet-to-dry ratio and histopathological damage. Furthermore, compared to the untreated ALI mice, Z.J extract at the highest dose could significantly reduce the TNF-α level. The present findings indicated that Z.J could effectively ameliorate LPS-induced ALI inflammatory responses and might be considered a promising alternative therapy for the ALI phenotype.
    Keywords Acute lung injury ; Inflammation ; Lipopolysaccharides ; Ziziphus ; Medicine ; R
    Subject code 630
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher Tehran University of Medical Sciences
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization

    Zebardast, Arghavan / Hosseini, Parastoo / Hasanzadeh, Ali / latifi, Tayebeh

    Molecular biology reports. 2022 Jan., v. 49, no. 1

    2022  

    Abstract: The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a ... ...

    Abstract The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.
    Keywords COVID-19 infection ; Camelidae ; Severe acute respiratory syndrome coronavirus 2 ; manufacturing ; molecular biology ; neutralization ; solubility ; therapeutics
    Language English
    Dates of publication 2022-01
    Size p. 647-656.
    Publishing place Springer Netherlands
    Document type Article
    Note Review
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-021-06819-7
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  9. Article ; Online: Ethanolic extract of

    Honari, Niloofar / Shaban, Parastoo / Nasseri, Saeed / Hosseini, Mehran

    Journal of complementary & integrative medicine

    2021  Volume 19, Issue 2, Page(s) 261–267

    Abstract: Objectives: Acute lung injury (ALI) is a life-threatening pulmonary dysfunction associated with severe inflammation. There are still no effective pharmacological therapies for the treatment of ALI. In this concern, several anti-inflammatory agents could ...

    Abstract Objectives: Acute lung injury (ALI) is a life-threatening pulmonary dysfunction associated with severe inflammation. There are still no effective pharmacological therapies for the treatment of ALI. In this concern, several anti-inflammatory agents could be used as add-on therapy to inhibit inflammation.
    Methods: The ALI model was established via the intra-tracheal (i.t.) administration of LPS (2 mg/kg) to male BALB/c mice. The ALI mice were divided into four groups (n=8 each) which intra-peritoneally (i.p.) treated with repeated doses of saline (model), dexamethasone (2 mg/kg), and AW (150-300 mg/kg) 1, 11 and 23 h post LPS administration. Twenty-four hours after the LPS challenge, bronchoalveolar lavage fluid (BALF) and lung tissue were evaluated for inflammatory cell influx, level of tumor necrosis factor-α (TNF-α) and histopathological changes.
    Results: The AW (150-300 mg/kg) treated mice showed lower inflammatory cells infiltration in BALF and TNF-α level when compared to the model group. In addition, LPS induced several pathological alterations such as edema, alveolar hemorrhage and inflammatory cell infiltration into the interstitium and alveolar spaces. Treatment with AW significantly reduced LPS-induced pathological injury.
    Conclusions: Taken together, the data here indicated that AW may be considered as a promising add-on therapy for ALI.
    MeSH term(s) Achillea ; Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Acute Lung Injury/pathology ; Animals ; Anti-Inflammatory Agents/adverse effects ; Inflammation/drug therapy ; Iran ; Lipopolysaccharides/adverse effects ; Lung/pathology ; Mice ; Mice, Inbred BALB C ; Plant Extracts/adverse effects ; Tumor Necrosis Factor-alpha
    Chemical Substances Anti-Inflammatory Agents ; Lipopolysaccharides ; Plant Extracts ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2021-05-06
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2197618-1
    ISSN 1553-3840 ; 2194-6329
    ISSN (online) 1553-3840
    ISSN 2194-6329
    DOI 10.1515/jcim-2021-0045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.

    Zebardast, Arghavan / Hosseini, Parastoo / Hasanzadeh, Ali / Latifi, Tayebeh

    Molecular biology reports

    2021  Volume 49, Issue 1, Page(s) 647–656

    Abstract: The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a ... ...

    Abstract The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.
    MeSH term(s) Animals ; Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/pharmacology ; Antibodies, Viral/chemistry ; Antibodies, Viral/immunology ; Antibodies, Viral/pharmacology ; COVID-19/immunology ; COVID-19/therapy ; Humans ; SARS-CoV-2/drug effects ; SARS-CoV-2/immunology ; Single-Domain Antibodies/chemistry ; Single-Domain Antibodies/immunology ; Single-Domain Antibodies/pharmacology ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/metabolism ; COVID-19 Drug Treatment
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Single-Domain Antibodies ; Spike Glycoprotein, Coronavirus
    Language English
    Publishing date 2021-10-14
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-021-06819-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top